Navigation Links
Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
Date:8/19/2010

SAN FRANCISCO, Aug. 19 /PRNewswire/ -- Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer, today announced the closing of a fully subscribed private placement financing with aggregate gross proceeds of approximately $8.6 million.

Proceeds from this transaction will be used to advance the Company's oncology product platform, led by JX-594, a novel oncolytic agent that has demonstrated promising antitumor activity in Phase 1 and Phase 2 clinical trials.

"This important round of financing provides us with funds necessary to continue to advance our pipeline of promising oncology products through clinical development and to achieve a number of corporate and clinical milestones.  This includes the completion of the ongoing JX-594 Phase 2 clinical trials currently underway for patients with liver cancer and colorectal cancer," said David H. Kirn, M.D., president and chief executive officer of Jennerex.  "We appreciate the support from many of our existing stockholders as well as a number of new important investors who chose to participate in this successful financing."

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer.  The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combination with sorafenib.  Prior, published studies designed to establish dose levels and the safety profile of JX-594 have shown its ability to selectively target a variety of common cancer tumor types.  JX-594 and other product candidates under development are designed to attack cancer tumors through three diver
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
2. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
3. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
6. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
7. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
8. Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
9. DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management
10. Resverlogix Completes Dosing for ASSERT Trial
11. Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013 Adding to their already ... stocked with Simport’s Dropette® and Heathrow Scientific disposable ... customer doing basic biology, chemistry and any type of ... For over 35 years, Simport has been supplying the ... products like the Simport Dropette®. Simport’s Dropette® is a ...
(Date:6/18/2013)... 18, 2013 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its preliminary unaudited financial results for the fourth ... March 31, 2013. Fourth Quarter of ... quarter of fiscal 2013 increased by 33.3% to RMB133.0 ...
(Date:6/18/2013)... USA (PRWEB) June 18, 2013 The ... the opening of two new offices in Asia—one in ... Singapore will serve as RAPS’ Pan-Asia office , ... will be more focused on audiences within China. , ... announced its partnership with five Singapore government agencies to ...
(Date:6/18/2013)... DuPont welcomes 48 of the nation’s finest ... AgriScience Teachers Ambassador Academy this week (NATAA) at the ... , The NATAA “Ag Academy” is a professional ... project of the National FFA Foundation and ... The highly recommended agriscience teachers, who are participating ...
Breaking Biology Technology:Leading Pipette Distributor Pipette.com Now Stocks Transfer Pipettes: Simport’s Dropette and Heathrow Scientific Disposable Plastic Transfer Pipettes 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 10China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 11China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 12China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 13RAPS Opens Offices in Singapore and China 2RAPS Opens Offices in Singapore and China 3DuPont Sponsors National AgriScience Ambassador Academy 2DuPont Sponsors National AgriScience Ambassador Academy 3
... ,The dial-in code is: 3684539 To view ... Upcoming Financial Date: February 2012 ... 2011 This press release contains statements about ... of these statements cannot be guaranteed as they are ...
... Oncology announces completion of a phase I Small Business ... Cancer Institute (NCI).  The SBIR grant project ... (JIT) to enroll cancer patients into clinical trials. ... with qualifying diagnoses across many research practices. Patients who ...
... Oct. 20, 2011 Med track is pleased ... 2011. Attendees of the show will be the first ... the newly designed platform. With deeply integrated datasets and ... professionals in business development, competitive intelligence and sales and ...
Cached Biology Technology:Nine-Month Figures for 2011: Dynamic, Profitable Growth at Sartorius 2Pharmatech Oncology Announces Completion of SBIR Grant Research 2Be One of the First to Experience the New Medtrack Platform at BIO®-Europe 2011 2
(Date:6/19/2013)... paper published in the journal Polar Biology, researchers report using ... may be a new type of killer whale ( Orcinus ... unusual-looking killer whales stranded on a New Zealand beach and ... were also taken but it was almost 50 years before ... small white eye-patch and bulbous forehead, was documented alive in ...
(Date:6/19/2013)... -- MedNet Solutions , a global life sciences ... pleased to announce its participation in the 2013 DIA ... Boston .  This represents the 10 th ... eClinical solutions, has exhibited at this premier industry event. ... EDC , MedNet,s latest, easy-to-use eClinical technology platform.  ...
(Date:6/19/2013)... bred specifically for human consumption qualifies as a gluten-free ... disease (CD), scientists have confirmed in a study published ... . , Joyce Irene Boye and colleagues point ... United States alone have CD. They develop gastrointestinal and ... grains that contain gluten-related proteins. Boye,s team sought to ...
Breaking Biology News(10 mins):MedNet Solutions To Spotlight iMedNet EDC At The 49th DIA Annual Meeting 2
... that links specific pieces of RNA to an infectious ... the prevention of viroids, pathogens that can kill or ... findings and the research approach used by Ohio State ... of how certain viruses spread in humans because the ...
... results of a University of Illinois study have demonstrated an ... bars. Eating two CocoaVia dark chocolate bars a day ... also lowering systolic blood pressure, said John Erdman, a U. ... The study, funded in part by Mars Inc., the company ...
... Multi-Modal Biometric Identification Solution ... and Interoperability, SCHAUMBURG, Ill., March 28 ... it has been selected by the West Virginia,State ... (BIS). Motorola,s latest BIS solution features new algorithms ...
Cached Biology News:Analysis of RNA role in spreading disease advances study of damaging plant infections 2Analysis of RNA role in spreading disease advances study of damaging plant infections 3Analysis of RNA role in spreading disease advances study of damaging plant infections 4Chocolate bar shown to lower cholesterol 2Motorola Biometric Identification System Selected by West Virginia State Police 2
OptiBuffer is a fully optimised medium, designed for,the electroporation of eukaryotic cells. OptiBuffer,improves both transfection efficiencies and survival,rates over PBS or other standard culture...
OmniSlide Heated Wash Module. 2 independent chambers with precise temperature control from ambient of 5C to 70C. Each chamber holds 1 slide rack (20 slides). Includes 2 x Wash Sleeves, 1 x Slide R...
HIV Reverse Transcriptase provides an excellent target for evaluating antiviral agents or catalyzing error prone synthesis on RNA and DNA templates....
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
Biology Products: